Complete responses to odronextamab in two patients with diffuse large B‐cell lymphoma refractory to chimeric antigen receptor T‐cell therapy

Outcomes remain poor for patients with relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL). While chimeric antigen receptor (CAR) T-cell therapy has revolutionised treatment, a significant proportion of patients relapse or fail to respond. Odronextamab is a CD20 x CD3 bispecific antibody that has demonstrated durable responses and a manageable safety profile in patients with R/R B-NHL in a first-in-human trial (NCT02290951). Here, we document two patients with diffuse large B-cell lymphoma refractory to CART-cell therapy. Both achieved complete responses that remain ongoing for >= 2 years following odronextamab. Neither patient experienced Grade >= 3 cytokine release syndrome or Grade >= 3 neurological adverse events during treatment.